title: Genetic polymorphisms in the PACAP and PAC1 receptor genes and treatment response to venlafaxine XR in generalized anxiety disorder.
abstract: The pituitary adenylate cyclase-activating peptide (PACAP) and its receptor (PAC1) are involved in stress response and anxiety. Genotypes for PACAP/PAC1 were examined for effects on treatment response to venlafaxine XR in generalized anxiety disorder. The Asp54Gly (rs2856966) variant in the PACAP gene was associated with better treatment outcome.
authors: Psychiatric Pharmacogenetics Laboratory, Center for Neurobiology and Behavior, Department of Psychiatry, University of Pennsylvania, United States.
authors: Alissa J
authors: AJ
authors: Cooper
authors: Sneha
authors: S
authors: Narasimhan
authors: Karl
authors: K
authors: Rickels
authors: Falk W
authors: FW
authors: Lohoff
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D003511:Cyclohexanols / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D008297:Male; D009479:Neuropeptides / Q000235:genetics; D010597:Pharmacogenetics; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000235:genetics*; D011110:Polymorphism, Genetic; D051237:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I / Q000235:genetics*; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D009479:Neuropeptides; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D051237:Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I; D000069470:Venlafaxine Hydrochloride
keywords: Anxiety disorders; Hypothalamic–pituitary–adrenal axis; Pharmacogenetics